ANDREW FORTNEY: Open Payments
NPI 1386369296 · CHESTER, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,135 in 20 payments from 8 companies in 2025. Trend: 2023 $130 · 2024 $107 · 2025 $1,135
Food & beverage: $1,135
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 5 | $369 |
| Janssen Pharmaceuticals, Inc | 7 | $322 |
| ABBVIE INC. | 2 | $132 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $104 |
| Alnylam Pharmaceuticals Inc. | 1 | $101 |
| Alkermes, Inc. | 2 | $60 |
| Neurocrine BioSciences, Inc. | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
Products named: INVEGA SUSTENNA, UZEDY, VRAYLAR, AUSTEDO XR, CAPLYTA, AMVUTTRA, ARISTADA, INGREZZA.
Industry payments across PA — which companies pay providers there.
